

## Increasing of PCOs among Young Females

Koloud Ateeq Alharbi<sup>1</sup>, Mohammed Meshal AlShathri<sup>2</sup>, Sajidah Alah Alshnqyta<sup>3</sup>, Safaa Mahmood Al-Hasani<sup>4</sup>, Mazin Ali Aaad Almosa<sup>5</sup>, Abdulrahman Mohammed Aljowair<sup>2</sup>, Osama Mohammed Alkhalifah<sup>6</sup>, Lina Emad Nouraldien<sup>1</sup>, Abdulrahman Omar Mansy<sup>7</sup>, Hadeel Lowthan Alshammari<sup>8</sup>

1 Ibn Sina National College For Medical Studies, Jeddah, Saudi Arabia, 2 Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia, 3 Taibah University, Al Madinah Al Munawarah , Saudi Arabia, 4 Batterjee Medical College For Science And Technology, Jeddah, Saudi Arabia, 5 King Khalid University, Abha, Saudi Arabia, 6 Mansoura University, Mansoura , Egypt, 7 Taif University, Altaif, Saudi Arabia, 8 Immam Abdulrahman Bin Faisal University, Al Dammam, Saudi Arabia

Corresponding Author: Koloud ateeq alharbi - [Khulod\\_alharbi@hotmail.com](mailto:Khulod_alharbi@hotmail.com) – 0508771942

### ABSTRACT

Polycystic ovary syndrome (PCOS) is a typical heterogeneous endocrine disorder characterized by irregular menses, polycystic ovaries, and hyperandrogenism. The pervasiveness of PCOS differs relying upon which criteria are utilized to make the diagnosis. Clinical manifestations incorporate oligomenorrhea or amenorrhea, hirsutism, and normally infertility. Risk factors for PCOS in adult women incorporates type I diabetes, type II diabetes, and gestational diabetes. Insulin resistance influences 50%–70% of women with PCOS prompting various comorbidities containing metabolic syndrome, dyslipidemia, diabetes, glucose intolerance, and hypertension. Studies demonstrate that women with PCOS will probably have expanded coronary artery calcium scores and increased carotid intima-media thickness. Mental health disorders comprising anxiety, depression, binge eating disorder and bipolar disorder similarly occur more often in women with PCOS. Weight loss advances menstrual irregularities, symptoms of androgen excess, and infertility. Management of clinical manifestations of PCOS comprises oral contraceptives for menstrual irregularities and hirsutism. Spironolactone and finasteride are used to treat symptoms of androgen excess. Treatment options for infertility include clomiphene, gonadotropins, laparoscopic ovarian drilling, and assisted reproductive technology. Appropriate diagnosis and administration of PCOS is crucial to address patient concerns yet additionally to anticipate future metabolic, endocrine, psychiatric, and cardiovascular complications.

**Keywords:** Polycystic ovary syndrome, diagnosis, treatment, Surgical Intervention.

### INTRODUCTION

The main features of polycystic ovarian syndrome (PCOS) comprise anovulation, menstrual dysfunction, and signs of hyperandrogenism <sup>[1]</sup>. While the exact etiopathophysiology of this condition is uncertain, polycystic ovarian syndrome may outcome from abnormal function of the hypothalamic-pituitary-ovarian (HPO) axis. A key characteristic of PCOS is unsuitable gonadotropin secretion, which is more probable a result of, afore a cause of, ovarian dysfunction. Furthermore, one of the most consistent biochemical features of polycystic ovarian syndrome is a raised plasma testosterone level <sup>[2]</sup>. Hyperandrogenism, a clinical assurance of PCOS, can cause inhibition of follicular development, micro-cysts in the ovaries, anovulation, and menstrual changes. Stein and Leventhal were the first to distinguish a relationship between the presence of polycystic ovaries and signs of hirsutism and amenorrhea (e.g., oligomenorrhea, obesity) <sup>[4]</sup>. After women diagnosed with Stein-Leventhal syndrome experienced successful wedge resection of the ovaries, their menstrual cycles became steady, and

they were capable of conceive. As a result, a primary ovarian defect was supposed to be the main culprit, and the disorder came to be identified as polycystic ovarian disease <sup>[5]</sup>.

Patients with polycystic ovarian syndrome (PCOS) have irregularities in the metabolism of estrogen and androgens and in the control of androgen creation.

High serum concentrations of androgenic hormones, as testosterone, androstenedione, and dehydroepiandrosterone sulfate (DHEA-S), might be experienced in these patients. Though, singular variety is impressive, and a specific patient may have usual androgen levels. Polycystic ovarian syndrome is additionally connected with peripheral insulin resistance and hyperinsulinemia, and obesity intensifies the degree of both abnormalities. Insulin resistance in PCOS can be optional to a post binding deficiency in insulin receptor signalling pathways, and elevated insulin levels can have gonadotropin augmenting consequences for ovarian task. Hyperinsulinemia might likewise bring about concealment of the hepatic generation of sex

hormone-binding globulin (SHBG), which in sequence can increase androgenicity [6]. Also, insulin resistance in PCOS has been related with adiponectin, a hormone emitted by adipocytes that manage lipid digestion and glucose levels. Lean and corpulent ladies with PCOS have lower adiponectin levels than do ladies without PCOS [7].

Investigations of relatives with PCOS show that an autosomal prevailing method of inheritance happens for some families with this ailment. The fathers of ladies with PCOS can be strangely hairy; female kin may have hirsutism and oligomenorrhea; and mothers might have oligomenorrhea. Investigation has recommended that in a substantial cohort of ladies with PCOS, a family history of type II diabetes in a first-degree relative is related with an expanded danger of metabolic irregularity, disabled glucose tolerance, and type II diabetes [8]. What's more, a Dutch twin-family study demonstrated a PCOS heritability of 0.71 in monozygotic twin sisters, versus 0.38 in dizygotic twins and other sisters [9]. PCOS affects premenopausal women, and the age of beginning is most regular perimenarchal before bone age reaches 16 years. On the other hand, clinical recognition of the syndrome might be postponed by failure of the patient to become worried by unbalanced menses, hirsutism, or other symptoms or by the overlap of PCOS results with normal physiologic maturation throughout the 2 years after menarche. In lean women with a genetic disposition to PCOS, the syndrome might be exposed when they consequently gain weight [6].

**MATERIALS AND METHODS**

• **Data Sources and Search terms**

We conducted this review using a comprehensive search of MEDLINE, PubMed, EMBASE, Cochrane Database of Systematic

Reviews, and Cochrane Central Register of Controlled Trials from January 1, 1988, through July 28, 2017.

• **Data Extraction**

Two reviewers independently reviewed studies, abstracted data, and resolved disagreements by consensus. Studies were evaluated for quality. A review protocol was followed throughout.

**The study was done after approval of ethical board of King Abdulaziz university.**

**Diagnostic criteria**

A 1990 expert conference sponsored by the National Institute of Child Health and Human Disease (NICHD) of the United States National Institutes of Health (NIH) proposed the following criteria for the diagnosis of PCOS [10] in table 1. In 2003, the European Society for Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) recommended that at least 2 of the following 3 features are required for PCOS to be diagnosed [11]. A research analysis done by Copp *et al* [12] pointed out that since the expanded criteria for PCOS diagnosis from the Rotterdam consensus, the estimated number of diagnoses in women of reproduction age increased from 4-6.6% to 21%. The Androgen Excess and PCOS Society (AE-PCOS) published a position statement in 2006 [13] and its criteria in 2009 [14] emphasizing that, in the society's opinion, PCOS should be considered a disorder of androgen excess. The Society of Obstetricians and Gynaecologists of Canada (SOGC) indicated that a diagnosis of polycystic ovarian syndrome (PCOS) is made in the presence of at least 2 of the following 3 criteria, when congenital adrenal hyperplasia, androgen-secreting tumors, or Cushing syndrome have been excluded [15].

**Table 1:** Criteria for the diagnosis of polycystic ovary syndrome

NIH/NICHD	ESHRE/ASRM (Rotterdam criteria)
Exclusion of other androgen excess or related disorders Includes all of the following: Clinical and/or biochemical hyperandrogenism Menstrual dysfunction	Exclusion of other androgen excess or related disorders Includes two of the following: Clinical and/or biochemical, hyperandrogenism Oligo-ovulation or anovulation Polycystic ovaries
Androgen Excess Society	The Society of Obstetricians and Gynaecologists
Exclusion of other androgen excess or related disorders Includes all of the following: Clinical and/or biochemical hyperandrogenism Ovarian dysfunction and/or polycystic ovaries	Oligo-ovulation or anovulation Clinical/biochemical evidence of hyperandrogenism Polycystic ovaries on ultrasonograms

### Polycystic Ovarian Syndrome Treatment

Certain lifestyle changes, such as diet and exercise, are reflected as a first-line treatment for teenage girls and women with polycystic ovarian syndrome. Pharmacologic treatments are reserved for so-called metabolic derangements, for example, hirsutism, anovulation, and menstrual irregularities. Medications for such conditions contain oral contraceptives, leuprolide, metformin, spironolactone, clomiphene, and prednisone [16]. Mean platelet volume (MPV) is a marker related with unfavorable cardiovascular occasions, and ladies with recently analyzed PCOS seem to have essentially raised MPV levels. **Kabil Kucur *et al.*** revealed that utilization of ethinyl estradiol/cyproterone acetic acid derivation or metformin for the treatment of ladies with PCOS appeared to have comparative gainful impacts in diminishing MPV [17]. Discussion with an endocrinologist is fundamental for playing out an adrenocorticotrophic hormone (ACTH) incitement test or for different reasons for menstrual anomaly, for example, thyroid infection or pituitary adenoma. A regenerative endocrinologist ought to be counselled if the patient is fruitless and wants pregnancy [18].

- **Drug Treatment**

Medical management of PCOS is intended at the treatment of metabolic derangements, hirsutism, anovulation, and menstrual irregularity. The utilization of insulin-sensitizing drugs to advance insulin sensitivity is related with a decline in circulating androgen levels, in addition to enhancement in both the glucose tolerance and ovulation rate [19]. The Endocrine Society has issued a clinical practice guideline on hirsutism assessment and treatment in premenopausal women [20]. ACOG notes that eflornithine in conjunction with laser treatment is superior to laser therapy alone in treating hirsutism [19]. First line management for ovulation induction when fertility is wanted is clomiphene citrate. Second line approaches might be equally operational in infertile women with clomiphene citrate resistant PCOS.

#### Metformin

In the event that the patient develops type II diabetes mellitus, consider treatment with oral antihyperglycemic medicines, for example, metformin. Metformin can likewise be considered in other ladies with PCOS who are insulin safe and subsequently in danger of creating cardiovascular illness, even ladies without type II diabetes. Clinical trials have demonstrated that metformin can viably diminish androgen levels, enhance insulin

affectability, and encourage weight reduction in patients with PCOS as ahead of schedule as the youth [21, 22]. One examination inferred that the utilization of metformin all through pregnancy was related with a 9-crease diminish in gestational diabetes in ladies with PCOS. Notwithstanding having the capacity to lessen gestational diabetes in pregnant ladies with PCOS, metformin may likewise decrease the danger of preeclampsia in this populace [23]. A long-term study recommended that metformin continued to develop the metabolic profile of women with PCOS in excess of a 36-month treatment course, mostly improving circulating high-density lipoprotein cholesterol (HDL-C), diastolic blood pressure, and body mass index (BMI) [24]. Nonetheless, data are inadequate so far to recommend metformin to all women with PCOS.

#### ⇒ Other agents

In the event that the patient has concomitant adrenal hyperandrogenism, treatment with low-measurement prednisone or dexamethasone might be considered. Depot leuprolide acetate (Lupron) is successful in stifling ovarian hormone generation, which adequately actuates menopause; consequently, this medication must be joined by hormone substitution treatment. This treatment approach has not increased extensive support. Numerous medications, comprising benzoyl peroxide, topical retinoids (Retin-A), and topical and oral antibiotics, are operative for acne treatment. Systemic isotretinoin is utilized for extreme or refractory cases.

### Anovulation

The Society of Obstetricians and Gynaecologists of Canada (SOGC) and American College of Obstetricians and Gynecologists (ACOG) recommend clomiphene citrate as first-line therapy to stimulate ovulation when fertility is anticipated [15, 19]. An alternative first line therapy to stimulate ovulation is letrozole [26].

Second-line therapy, when clomiphene citrate flops to lead to pregnancy, is whichever exogenous gonadotropins or laparoscopic ovarian surgery. If gonadotropins are used, a low-dose regimen is mentioned, and patients should be monitored with ultrasonography and laboratory studies. Note that gonadotropin treatment is expensive and is allied with an increased danger of multiple pregnancy and ovarian hyperstimulation syndrome [15, 19].

Confirmation recommends that metformin as often as possible, yet not generally, enhances ovulation rates and pregnancy rates in ladies with polycystic ovarian disorder (PCOS), particularly in

large ladies [26]. Likewise, pre-treatment with metformin has been appeared to improve the viability of clomiphene for inciting ovulation. Consider the blend of metformin and clomiphene in more established ladies with instinctive stoutness and clomiphene protection. However, this blend doesn't essentially enhance the live birth rate in respect to clomiphene monotherapy. Whether short-course metformin pretreatment (less than a month) is as powerful as customary long-course metformin stays indeterminate [27]. An examination found that N-acetylcysteine may upgrade the impact of clomiphene citrate in initiating ovulation in patients with PCOS [28].

Patients with PCOS who are infertile but want pregnancy ought to be referred to a reproductive endocrinologist for more assessment and administration of infertility. Morbidly obese women with PCOS ought to similarly be stated for pregnancy hazard; metabolic surgery can be considered in morbidly obese women with PCOS, as numerous features of this syndrome are revocable with successful weight loss. In vitro fertilization (IVF) is reserved for women with PCOS and unsuccessful gonadotropin treatment or those with other indications for this process [15]. A study by Chen et al discovered that between infertile female with PCOS, frozen-embryo transfer was related with a higher rate of live birth, a lower danger of the ovarian hyper stimulation syndrome, and a higher danger of preeclampsia after the principal transfer than was fresh-embryo transfer [29].

- **Lifestyle Modifications**

The American College of Obstetricians and Gynecologists (ACOG) and the Society of Obstetricians and Gynecologists of Canada (SOGC) demonstrate that way of life alterations, for example, weight reduction and expanded exercise in conjunction with an adjustment in consume less calories reliably diminish the danger of diabetes. This approach has been observed to be practically identical to or superior to treatment with medicine and ought to in this manner be viewed as first-line treatment in overseeing ladies with polycystic ovarian disorder [15, 19]. These adjustments have been viable in re-establishing ovulatory cycles and accomplishing pregnancy in hefty ladies with PCOS. Weight reduction in fat ladies with PCOS additionally enhances hyperandrogenic highlights.

- **Surgical Intervention**

Surgical Intervention of polycystic ovarian syndrome is intended mostly at restoring ovulation. Ovarian wedge resection has fallen out of favour

due to postoperative adhesion formation and the successful introduction of ovulation-inducing medications. Various laparoscopic approaches, comprising laser drilling, electrocautery, and multiple biopsy, have been used with the aim of creating focal areas of harm in the ovarian cortex and stroma. Consistent with the Society of Obstetricians and Gynaecologists of Canada (SOGC), laparoscopic ovarian drilling can be reflected in women with clomiphene-resistant PCOS, particularly in the presence of other laparoscopic indications [15]. A study likewise recommended that surgical management through ovarian drilling with hydrolaparoscopy can be beneficial in cases of PCOS that are resistant to clomiphene citrate [30].

Possible complications should be considered as well. These contain formation of adhesions and ovarian atrophy. Multiple pregnancy rates are lower with ovarian drilling than with gonadotropin treatment (1% vs. 16%, respectively), but there are on-going apprehensions about the long-term effects of ovarian drilling on ovarian function [31].

- **Hirsutism**

A clear major treatment for hirsutism in women with PCOS stays lacking. Nonetheless, short-term, non-pharmacologic treatments of hirsutism incorporate shaving and the utilization of chemical depilatories and bleaching cream [32]. Plucking or waxing unwanted hair can result in folliculitis and ingrown hairs. Long-term, more lasting measures for unwanted hairs incorporate electrolysis and laser treatment. Adjunctive eflornithine with laser treatment is better than laser treatment alone in treating hirsutism. Eflornithine (Vaniqa) is a topical cream that can be utilized to moderate hair development. This specialist works by hindering ornithine decarboxylase, which is fundamental for the quickly isolating cells of hair follicles. Weight loss decreases androgen production in women who are obese; thus, losing weight can slow hair growth. Ladies who don't wish to wind up plainly pregnant can be successfully treated for hirsutism with oral contraceptives. [77] Oral contraceptives moderate hair development in 60-100% of ladies with hyperandrogenemia. Treatment can be begun with an arrangement that has low measurements of estrogen and a nonandrogenic progestin. Arrangements that have norgestrel and levonorgestrel ought to be kept away from in view of their androgenic action. There is additionally a danger of thrombotic occasions in fat ladies who utilize oral contraceptives; in this manner, the best possible safeguards ought to be practiced to avert

such occasions. Oral contraceptives containing cyproterone acetic acid derivation are likewise exceptionally powerful in the treatment of more extreme hirsutism<sup>[33]</sup>; be that as it may, this mix of operators has not been endorsed by the FDA for use in the United States. Antiandrogens, such as spironolactone, are viable for hirsutism. [79] Spironolactone (50-100 mg twice every day) is a compelling essential treatment for hirsutism. In light of the potential teratogenic impacts of spironolactone, patients require a successful type of contraception (eg, an oral preventative). Unfavourable impacts of spironolactone incorporate gastrointestinal uneasiness and unpredictable menstrual dying, which can be overseen by including an oral prophylactic. Ovulation induction with clomiphene citrate, metformin, or both does not alter hirsutism in infertile hirsute women with PCOS<sup>[34]</sup>.

## CONCLUSION

Proper diagnosis and management of PCOS is vital as polycystic ovary syndrome has many potential metabolic and cardiovascular hazards if not managed correctly. It is clear that the underlying pathophysiology of polycystic ovary syndrome is not fully understood. Accordingly, management is regularly focused on individual symptoms, not the syndrome itself. Nonetheless, as the understanding of the pathophysiology of polycystic ovary syndrome advances, so does the treatment. Even though treatment ought to be individualized, it ought to similarly focus on all metabolic outcomes and decreasing future complications. More extensive research and understanding of the pathophysiology of polycystic ovary syndrome will improve treatment success and overall management of patients.

## REFERENCES

- Azziz R, Carmina E, Dewailly D et al.(2009):** Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. *Fertil Steril.* , 91(2):456-88.
- Barber TM, Franks S(2010):** Genetic basis of polycystic ovary syndrome. *Expert Review of Endocrinology & Metabolism*, 5(4):549-61.
- Lin LH, Baracat MC, Gustavo AR et al.(2013):** Androgen receptor gene polymorphism and polycystic ovary syndrome. *Int J Gynaecol Obstet.*,120:115–118.
- Stein I, Leventhal M(1953):** Amenorrhea associated with bilateral polycystic ovaries. *Am J Obstet Gynecol.* , 29:181.
- Stein IF(1964):** Duration of infertility following ovarian wedge resection. *West J Surg.*, 72:237.
- Barber TM, McCarthy MI, Wass JA, Franks S (2006):**Obesity and polycystic ovary syndrome. *Clin Endocrinol (Oxf)*,65(2):137-45.
- Toulis KA, Goulis DG, Farmakiotis D et al. (2009):**Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. *Hum Reprod Update*, 15(3):297-307.
- Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN(2005):** Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. *J Clin Endocrinol Metab.* , 90(1):66-71.
- Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI(2006):** Heritability of polycystic ovary syndrome in a Dutch twin-family study. *J Clin Endocrinol Metab.*,91(6):2100-4.
- Zawadzki JK, Dunaif A(1992):** Diagnostic criteria for polycystic ovary syndrome. In: Givens JHF, Merriman G, editors. *The Polycystic Ovary Syndrome*. Cambridge, MA: Blackwell Scientific, pp. 377–384.
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group(2004):** Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril.* ,81:19–25.
- Copp T, Jansen J, Doust J, Mol BW, Dokras A, McCaffery K(2017):** Are expanding disease definitions unnecessarily labelling women with polycystic ovary syndrome?. *BMJ.* , 358:j3694
- Azziz R, Carmina E, Dewailly D et al.(2006):** Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. *J Clin Endocrinol Metab.*,91(11):4237-45.
- Azziz R, Carmina E, Dewailly D et al.(2009):** The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. *Fertil Steril.* , 91(2):456-88.
- Vause TD, Cheung AP, Sierra S et al.(2010):** Ovulation induction in polycystic ovary syndrome. *J Obstet Gynaecol Can.* , 32(5):495-502.
- Hecht Baldauff N, Arslanian S(2015):** Optimal management of polycystic ovary syndrome in adolescence. *Arch Dis Child*, 100 (11):1076-83
- Kabil Kucur S, Gozukara I, Aksoy A et al.(2015):** How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?. *Blood Coagul Fibrinolysis*, 26 (8):862-5.
- Trent ME, Rich M, Austin SB, Gordon CM(2003):** Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome: implications for quality of life. *J Pediatr Adolesc Gynecol.*,16(1):33-7.
- American College of Obstetricians and Gynecologists(2009):** Polycystic ovary syndrome. Washington, DC: American College of Obstetricians and Gynecologists. [www.aacp.org/resources/.../whc/.../PolycysticOvarySyndromeCoreModule03-18-15.d..](http://www.aacp.org/resources/.../whc/.../PolycysticOvarySyndromeCoreModule03-18-15.d..)

20. **Martin KA, Chang RJ, Ehrmann DA *et al.* (2008):** Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab.*, 93(4):1105-20.
21. **Otta CF, Wior M, Iraci GS *et al.* (2010):** Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. *Gynecol Endocrinol.*, 26(3):173-8.
22. **Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS (2004):** A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. *Fertil Steril.*, 82(2):421-9.
23. **Khattab S, Mohsen IA, Aboul Foutouh I *et al.* (2011):** Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. *Gynecol Endocrinol.*, 27(10):789-93.
24. **Cheang KI, Huszar JM, Best AM, Sharma S, Essah PA, Nestler JE (2009):** Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. *Diab Vasc Dis Res.*, 6(2):110-9.
25. **Legro RS, Brzyski RG, Diamond MP *et al.* (2014):** Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. *N Engl J Med.* , 371(2):119-29.
26. **Leeman L, Acharya U (2009):** The use of metformin in the management of polycystic ovary syndrome and associated anovulatory infertility: the current evidence. *J Obstet Gynaecol.* , 29(6):467-72.
27. **Sinawat S, Buppasiri P, Lumbiganon P, Pattanittum P (2008):** Long versus short course treatment with metformin and clomiphene citrate for ovulation induction in women with PCOS. *Cochrane Database Syst Rev.*, <https://www.ncbi.nlm.nih.gov/pubmed/18254096>
28. **Badawy A, State O, Abdelgawad S (2007):** N-Acetyl cysteine and clomiphene citrate for induction of ovulation in polycystic ovary syndrome: a cross-over trial. *Acta Obstet Gynecol Scand.* 86(2):218-22.
29. **Chen ZJ, Shi Y, Sun Y *et al.* (2016):** Fresh versus Frozen Embryos for Infertility in the Polycystic Ovary Syndrome. *N Engl J Med.*, 375(6):523-533.
30. **Poujade O, Gervaise A, Faivre E, Deffieux X, Fernandez H (2011):** Surgical management of infertility due to polycystic ovarian syndrome after failure of medical management. *Eur J Obstet Gynecol Reprod Biol.*, 158(2):242-7.
31. **Farquhar C, Lilford RJ, Marjoribanks J, Vandekerckhove P (2007):** Laparoscopic 'drilling' by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. *Cochrane Database Syst Rev.* <https://www.ncbi.nlm.nih.gov/pubmed/17636653>
32. **Koulouri O, Conway GS (2009):** Management of hirsutism. *BMJ.* , 338:b847.
33. **Paparodis R, Dunaif A (2011):** The Hirsute woman: challenges in evaluation and management. *Endocr Pract.*, 17(5):807-18.
34. **Roth LW, Huang H, Legro RS *et al.* (2012):** Altering hirsutism through ovulation induction in women with polycystic ovary syndrome. *Obstet Gynecol.*, 119(6):1151-6.